CLAIMS

1. Nonpathogenic nonfilamentous Gram-negative bacterium belonging to the class of *Betaproteobacteria*, subfamily of *Neisseriaceae*, characterized in that the nucleotide sequence of the 16S rRNA gene of said bacterium includes sequence SEQ ID No. 1 and.

~~2. Bacterium according to claim 1, characterized~~ in that it includes at least one plasmid comprising sequence SEQ ID No. 2, or any sequence with at least 80% identity with said sequence SEQ ID No. 2.

~~3. Bacterium according to claim 1 or claim 2, characterized in that it is nonfilamentous.~~

~~4.~~2. Bacterium according to ~~any one of~~ claims ~~1 to 3~~, deposited with the CNCM on April 8, 2010, under the reference I-4290, or any other mutant directly arising from strain I-4290.

~~5.~~3. Bacterial extract obtained from a suspension of bacteria according to any one of claims 1 and 2~~to 4~~.

~~6.~~4. Bacterial extract according to claim ~~5~~3, characterized in that it is obtained after treatment of said bacterial suspension in such a way as to eliminate the intracellular components.

~~7.~~5. Bacterial extract according to claim ~~6~~4, characterized in that said intracellular components include at least the nucleic acids.

~~8.~~6. Bacterial extract according to claim ~~6~~4 or claim ~~7~~5, characterized in that it includes a fraction E0 comprising at least membrane proteins, periplasmic proteins and proteins arising from the flagellum.

~~9.~~7. Bacterial extract according to claim ~~8~~6, characterized in that said membrane proteins consist of porins, OmpA, lipopolysaccharides and/or lipoproteins.

~~10.~~8. Bacterial extract according to claim ~~6~~4 or claim ~~7~~5, characterized in that it includes a fraction S0 comprising at least secreted peptides and proteins and secondary metabolites.

~~11.~~9. Bacterial extract according to claim ~~6~~4 or claim ~~7~~5, characterized in that it includes a fraction ES0 comprising at least fraction E0 and fraction S0.

~~12.~~10. Bacterial extract according to claim ~~11~~9, characterized in that it includes a fraction ES0 with a protein profile, obtained by SDS-PAGE, which includes three

principal bands corresponding to molecular weights ranging between 30 kDa and 36 kDa, 41 kDa and 45 kDa, and 47 kDa and 51 kDa, respectively.

~~13. Use of a bacterium according to any one of claims 1 to 4 and/or a bacterial extract according to any one of claims 5 to 9 and 12 for the preparation of a composition intended for the activation of TLR2, TLR4 and TLR5.~~

~~14. Use of a bacterium according to any one of claims 1 to 4 and/or a bacterial extract according to any one of claims 10 or 12 for the preparation of a PAR2 antagonist composition.~~

~~15.~~11. Use of a bacterium according to any one of claims 1 ~~to 4~~and 2 and/or a bacterial extract according to any one of claims ~~5~~3 to ~~12~~10 for the preparation of a composition intended for the treatment and/or the prevention of dermatological inflammatory disorders.

~~16.~~12. Use according to claim ~~13~~11, characterized in that said dermatological inflammatory disorders consist of atopic dermatitis, pruritus, eczema and psoriasis.

~~17.~~13. Composition comprising, as an active ingredient, at least one bacterium according to any one of claims 1 ~~to 4~~and 2 and/or one bacterial extract according to any one of claims ~~5~~3 to ~~12~~10.

~~18.~~14. Composition according to claim ~~15~~13, for the treatment of dermatological inflammatory disorders.

~~19.~~15. Composition according to claim ~~18~~14, characterized in that said dermatological inflammatory disorders consist of atopic dermatitis, pruritus, eczema and psoriasis.

~~20.~~16. Cosmetic or dermatological composition according to any one of claims ~~17~~13 to ~~19~~15, characterized in that it further includes one or more typical dermatologically-compatible excipients.